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Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia as it accounts for 60-80% of all dementia cases. According to the recent World Alzheimer's Report, the population of patients suffering from AD is expected to reach 115.4 million by 2050. The disease is characterized by the presence of senile plaques, neurofibrillary tangles and loss of neurons that together result in cognitive impairment and memory loss [1] [2] [3] . The multifactorial nature of AD presents significant challenges, both in terms of understanding pathological mechanisms and for the development of therapeutics [4] . The oxidative stress hypothesis of AD identifies lipid and protein oxidation as potential initiators and propagators of the pathways contributing to AD [5] [6] [7] . Interestingly, oxidative stress is one of the early events in AD pathology and may even precede amyloid plaque formation [8, 9] .
Oxidative stress involves oxidation of proteins, lipids, nucleic acids and sugars. Evidence from an increasing number of studies indicates biochemical markers of oxidative stress are significantly increased in the AD brain [10] [11] [12] . The brain is suggested to be highly susceptible to lipid peroxidation due to high levels of polyunsaturated fatty acids, high metabolic oxidative rate, high level of transition metal ions and relatively low levels of antioxidants [13] . It has been reported that the levels of lipid peroxidation increase before amyloid plaque formation in AD [9, 14, 15] . Products of lipid peroxidation that are found to be elevated in several brain regions of AD patients compared to control subjects include lipid conjugated dienes, 4-hydroxynonenal (4-HNE), 4-hydroxyhexenal (4-HHE), acrolein, thiobarbituric acid reactive-substances (TBARS), and F 2 -isoprostanes [9, [16] [17] [18] [19] [20] .
Apolipoprotein D (ApoD) is a multifunctional, phylogenetically conserved glycoprotein with widely distributed expression in mammalian tissues [21] [22] [23] . Although it is mainly synthesized by glial cells in the brain, apoD may also be expressed in neurons in association with aging and in several pathological conditions [24, 25] . ApoD is upregulated in the brain under oxidative stress conditions including in aging, AD, Parkinson's disease and Schizophrenia [26] [27] [28] [29] [30] [31] . Several lines of evidence including the increase in apoD expression with AD progression [26, 29, 32] , colocalisation of apoD with diffuse amyloid plaques in AD brain [33] , and induction of apoD synthesis in hippocampal cells treated with Aβ 25-35 [34] , raise the possibility that apoD may be upregulated as a neuroprotective response in AD.
ApoD has been highlighted as a brain lipid antioxidant in previous studies. ApoD null (apoD -/-) mice show increased sensitivity to oxidative stress whereas transgenic mice overexpressing human apoD (h-apoDtg) show a reduction in brain lipid peroxidation levels when treated with paraquat as an inducer of oxidative stress [35] . Similarly, deletion of glial lazarillo, a homolog of apoD, reduced oxidative stress resistance in Drosophila [36] , whereas over-expression of apoD was associated with reduced accumulation of aldehydic endproducts of lipid peroxidation in an aged Drosophila model [37] . In addition, apoD provides protection against kainic acid lesion in rat hippocampal neurons by inhibiting lipid peroxidation as assessed by reduced levels of F 2 -isoprostanes, 7-ketocholesterol and 4-HNE [38] . It is therefore plausible that apoD may act as a neuroprotectant in AD by reducing brain lipid peroxidation.
In our previous studies we demonstrated that apoD acts as a lipid antioxidant by reducing lipid hydroperoxides to lipid hydroxides in a 2-electron reduction that is dependent on a single surface-exposed Met residue at position 93 [23] . As a consequence of this reaction, apoD Met 93 is converted to Met sulfoxide (MetSO). Our in vitro and in silico studies revealed that this modification of apoD Met 93 to MetSO was found to destablilize the protein structure and promote self association that resulted in the formation of a stable (but non-covalent) homodimer [23, 39] . Interestingly, such apoD dimers were also observed in the insoluble fractions of postmortem hippocampal tissue homogenates derived from a small set (n=3) of late stage AD cases [23] .
The objective of the current study was to assess a larger cohort of age-matched control and AD subjects (classified according to Braak staging) to determine the stage of disease at which apoD dimers may be formed and to examine the relationship between apoD dimer formation and measures of brain lipid peroxidation.
Material and Methods

Human brain tissue
Human brain tissues were received from the New South Wales Tissue Resource Centre and the Sydney Brain Bank. Patient data and brains were collected for research purposes as approved by institutional Human Ethics Committees. The use of human brain tissue for this project was approved by the University of Wollongong Human Research Ethics Committee (HE10/327). ). Cases were screened using standardized protocols to confirm the presence of AD and exclude coexisting cerebrovascular and degenerative pathologies. Tissue pH was determined on a sample of cerebellum from each case. Braak staging of AD type pathology was performed on sections of the hippocampal formation and temporal cortex according to published criteria [40] . We confirm that all procedures involving experiments on human subjects are done in accord with the Helsinki Declaration of 1975. The APOE genotype of all samples was determined by PCR as described previously [41] . Briefly, genomic APOE was amplified using the forward: TCCAAGGAGCTGCAGGCGGCGCA and reverse:
ACAGAATTCGCCCCGGCCTGGTACACTGCCA primers and double digested with HaeII and AflIII. The presence of an ε4 allele was indicated by resistance to AflIII digestion, whilst the presence of an ε2 allele was indicated by resistance to HaeII digestion.
Protein analysis -sample preparation
Brain tissue homogenates were prepared by homogenizing ~60 mg tissue in 6 volumes of ice 
Western blotting
Sample protein concentrations were determined using BCA assay and equal amounts of protein were separated on 12% SDS PAGE gels at 140 V for 80 min, followed by transfer at 100 V for 30 min onto 0.45 µm nitrocellulose membranes. The membranes were blocked in 5% skim milk in phosphate-buffered saline (PBS) for 1 h at 22°C and then probed with anti apoD mouse monoclonal antibody (Sapphire Bioscience 36C6 clone, 1/2000 dilution) at 4°C for 16 h followed by incubation with horseradish-conjugated rabbit anti mouse (Dako 1/2000 dilution) polyclonal antibody for 1 h at 22°C. Membranes were washed and protein was detected using enhanced chemiluminescence (ECL, Amersham Biosciences) and X-ray film.
Membranes were stripped and re-probed for β-actin to confirm equal protein loading. The signal intensity was quantified using NIH ImageJ software. All samples were analysed by western blotting with mean values of the resulting data presented in the histograms and representative samples selected for display in the western blot panels.
ELISA
The concentration of Aβ40 and Aβ42 in brain homogenates was determined using Beta Mark 
Lipid analysis -sample preparation
Samples for lipid analysis were prepared by homogenizing 20 mg of frozen tissue in 0.6 ml methanol, 0.01% (v/v) butyalted hydroxytoluene (BHT) with internal standards for GC-MS analysis. Homogenized fractions were divided into aliquots that were processed separately for analysis of conjugated dienes by HPLC or for F 2 -isoprostanes by GC-MS. To the aliquots (0.4 ml) to be used for conjugated diene analysis, (methyl-tert-butyl ether) MTBE was added so that the methanol to MTBE ratio was 3:10 (v/v). Sodium hydroxide (final concentration 0.7 M) was added for hydrolysis of ester bonds and the samples were vortex mixed and incubated at 4°C for 16 h in a rotator. This was followed by the addition and mixing of 0. 
Analysis of lipid oxidation markers by HPLC and GC-MS
Conjugated dienes and free fatty acids (40 µl aliquot) were analyzed using a 5µm, 25 x 0.46 cm, C18 reversed phase column at a flow rate of 1 ml / min at 22°C. The mobile phase used was 0.1% acetic acid in H 2 O-acetonitrile-tetrahydrofuran (45:45:10 v/v/v) with UV234 nm absorbance detection. Lipid conjugated dienes are formed as a consequence of free radicalmediated hydrogen abstraction from lipid methylene groups and subsequent molecular rearrangement to stabilize the resulting carbon-centered radical [42] . Lipid conjugated dienes are a relatively stable marker of lipid peroxidation that have been shown to be increased in postmortem human Alzheimer's disease brain tissues compared to controls [43] and are also induced in animal models of neurodegeneration and injury [44] .
The solvent extracted isoprostane fraction (see "Lipid sample preparation" above) was dried down under nitrogen at 37°C and derivatized with 30 µl of pentafluorobenzylbromide (PFBBr, 10% in acetonitrile) and 15 µl of N,N-diisopropylethylamine (DIPEA, 10% in acetonitrile) at 37°C for 30 min. Excess reagents were evaporated under N 2 . The F 2 -isoprostane PFBenzyl esters were then derivatized with 15 µl acetonitrile + 30 µl BSTFA + 1% TMCS for 1 h at 37°C. After drying under N 2 and reconstitution in 30 uL toluene, derivatized samples were analyzed by an Agilent 7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC system gas chromatograph, equipped with an automatic sampler and a computer workstation. The injection port and GC-MS interface were kept at 270°C. Separations were carried out on a fused silica capillary column (20 m x 0.18 mm i.d. x 0.18 µm film thickness, Restek Rxi-5ms). Helium was the carrier gas with a flow rate of 0.8 ml/min (average velocity = 59 cm/sec). Selected-reaction monitoring (SRM) was performed using the NCI mode (70eV) with Ar as the reagent gas (1.25 ml/min) and the collision gas (0.6 ml/min). The ion source was maintained at 150°C and the quadrupoles at 150°C. For F 2 -isoprostane analysis derivatized samples (1 µl) were injected splitless into the GC injection port. Column temperature was increased from 180°C to 280°C at 40°C / min after 1 min at 180°C, then temperature was raised to 290°C at 2°C / min, then at 40°C / min to 305°C with a final hold for 4 min. Quantification of F 2 -isoprostanes was calculated by comparison of specific SRM transitions with their corresponding heavy isotope internal standards.
Statistics
Group comparisons were made using ANOVA with Fisher's least significant difference (LSD) post-hoc analysis. Where specific comparisons were made between two groups a t-test was applied. Pearson correlations were used to assess relationships between biochemical parameters and linear regression analysis was used to assess the strongest correlates of apoD dimer formation. Variance inflation factor (VIF) values were assessed in order to quantify multicolinearity. VIF values greater > 5 were considered as an indicator of high multicolinearity [45] . Statistical testing was performed using SPSS Statistics (version 19) software, IBM Company).
Results
Characterisation of AD brain samples
Basic clinical and demographic data for the samples used in this study are provided in Table   1 . The samples were stratified into four groups of disease severity using clinically and pathologically defined National Institute on Aging-Reagan criteria as described previously [46, 47] . Thirty four samples were obtained in total including nine cases of normal control brain. The "severity of disease" groupings according to Braak pathology are provided in Table 1 . There were no significant group effects for age, postmortem interval (PMI) or sample pH as assessed by ANOVA. Post-hoc analysis using Fisher's LSD test revealed a lower average PMI in Group V/VI samples compared to both Group I/II and Group III/IV (both p < 0.05). There were no significant correlations between PMI and any of the demographic or biochemical parameters measured (data not shown) in any of the groups and it is therefore unlikely that PMI is a confounding factor in this study.
Braak staging of disease progression is based on the distribution of neurofibrillary tangles.
The formation of neurofibrillary tangles is a tau-mediated process and is not unique to AD; (Fig. 1) . Levels of hippocampal soluble Aβ40 did not change significantly when the different groups were analyzed (Fig. 1) .
The lack or correlation between the Braak staging and Aβ levels across AD stages is most likely due to differences in topographic distributions of neurofibrillary tangles and plaque pathology in AD. Neurofibrillary tangles (which form the basis of the Braak staging used in the current study) begin to appear in the allocortex of the medial temporal lobes (including the hippocampus) and only in the late stages of disease do they appear in the isocortical areas [48] . In contrast, Aβ accumulates mainly in the isocortex whereas the allocortex (including the hippocampus) is generally involved to a lesser extent until the final stages of disease [48, 49] . The changes we observed in Aβ40 levels are very minor when compared to Aβ42; in agreement with previous studies indicating Aβ42 as the predominant pathological Aβ species [1] .
Overall, these data confirm the diagnosis of the late stage AD cases and also confirm that deposition of insoluble Aβ is more pronounced in the hippocampus compared to the cerebellum. These two regions can therefore be used to assess relative changes in affected versus non-affected brain regions, respectively.
Hippocampal apoD expression is associated with AD Braak stage
Previous studies have shown that apoD levels are increased in human AD brain tissues compared to controls [23, 26, 32, 33] . One study has also shown that the expression of apoD in the hippocampus increases with disease severity as assessed by Braak staging [29] . In the current study we first assessed apoD levels in different stages of AD in both the hippocampus and cerebellum. In agreement with previous observations, hippocampal TBS-soluble apoD levels were significantly associated (ANOVA p = 0.038) with AD Braak stage (Fig 2A) . There were no significant differences detected for apoD in the cerebellum (Fig. 2B) .
One of the earlier studies showing that apoD is increased in the AD hippocampus reported that the increase was dependent on APOE genotype, whereby AD cases who carried at least one ε4 allele did not show significant variations in hippocampal apoD expression [29] .
Intriguingly, another study published in the same year showed that the increase in apoD levels detected in the prefrontal cortex from AD cases was not related to APOE genotype [32] . In our current study, the numbers of subjects expressing each of the APOE genotypes was not sufficiently powered to examine the impact of genotype on apoD expression across all groups; however, a t-test analysis comparing the four APOE ε3/4 heterozygotes in the control group (Group 0) samples to the five APOE ε3/4 heterozygotes in the late stage AD (Group V/VI) samples indicated a significant increase in relative hippocampal apoD levels (Group 0, 1.00 + 0.16 versus Group V/VI, 1.90 + 0.12; values are means + SE; p = 0.003).
This suggests that increased hippocampal apoD expression in AD is not influenced by the presence of a single ε4 allele.
Hippocampal apoD dimerization increases in late stage AD
In our previous study we revealed that apoD exists as a dimer in the gHCl soluble fraction of a relative small number (n = 3) of late stage AD hippocampal samples compared to controls [23] . We therefore next examined the formation of apoD dimers in association with AD stages. Western blot analysis revealed that apoD dimers were detected at increased levels (ANOVA p = 0.0164) in the AD cases (Fig. 3A) . Although the ~50kDa apoD dimer band was occasionally detected in less severe AD cases, post-hoc analysis revealed a significant increase only in the Group V/VI samples (p = 0.009, p = 0.012, p = 0.012 compared to Group 0, Group I/II and Group III/IV, respectively). We could detect only very low levels of apoD in the gHCl soluble fractions of the cerebellum samples and apoD dimers were also not reliably detected in the cerebellum (Bhatia S. and Garner B., unpublished observations).
It is interesting to note that overall hippocampal apoD expression appears to increase in proportion to disease severity (Fig 2A) , whereas the levels of apoD dimer appear to significantly increase only in the later stages of AD (Fig. 3A) . It is also noteworthy that neither apoD nor apoD dimer levels appear to increase in the cerebellum (a region that is relatively unaffected in AD). This suggests that the altered apoD expression may be related to AD pathological processes.
Lipid peroxidation markers increase in AD hippocampus
To investigate possible associations between apoD and lipid peroxidation in AD, we measured levels of lipid-associated conjugated dienes (by absorbance at UV234 nm) and levels of F 2 -isoprostanes (by GC-MS). Both are established methods for assessing lipid peroxidation in brain tissues [42] . We detected a significant increase (ANOVA p = 0.002) in conjugated dienes in late stage AD (Fig. 4A) . Post-hoc analysis revealed a significant increase only in the Group V/VI samples (p = 0.001, p = 0.001, p = 0.006 compared to Group 0, Group I/II and Group III/IV, respectively). There were no changes in conjugated dienes in relation to AD status in any of the cerebellum samples (Fig 4B) . Levels of F 2 -isoprostanes did not differ significantly in relation to AD status in either the hippocampus or cerebellum as assessed by ANOVA (Fig. 5) . Post-hoc analysis revealed a significant increase in hippocampal F 2 -isoprostane levels only in the Group III/IV samples (p = 0.025) compared to Group 0 (Fig. 5) .
Previous studies have suggested that markers of brain lipid peroxidation may increase in specific brain regions with extended PMI [50, 51] . In the present study cohort the median PMI was 17.5 h (20.5 + 2.8 h, mean + SE, n = 34). Importantly, PMI was not significantly associated with increased conjugated diene or F 2 -isoprostane levels (Pearson correlation coefficients r 2 = -0.178 and 0.004, respectively). It is therefore unlikely that PMI was a confounding factor in our assessment of lipid peroxidation as a function of AD stage;
however, we cannot rule out a possible global contribution of PMI to overall levels of conjugated dienes or F 2 -isoprostanes across the study cohort.
Associations between hippocampal apoD dimer formation and markers of lipid peroxidation
The data presented above indicate that apoD dimer formation is significantly higher in late stage AD, although clearly there are cases in other groups where the dimer was detected (Fig. 3 ). In order to understand which of the factors we have assessed correlates with apoD dimer levels, Pearson correlations were examined. The data presented in Table 2 indicates that lipid conjugated diene concentration (UV234 absorbance) was the only variable signficiantly correlated (p = 0.006) with apoD dimer levels. Interestingly, soluble apoD and soluble Aβ42
were also correlated (p = 0.025 and p = 0.004, respectively) with conjugated diene concentration ( Table 2 ). Levels of both insoluble and soluble Aβ42 and Aβ40 were all significantly intercorrelated (Table 2) , whereas there were no significant correlates of F 2 -isoprostanes in this analysis ( Table 2 ). To gain additional insights into the strengths of these correlations, we performed linear regression analysis.
Using apoD dimer as the dependent variable, the other seven variables measured (apoD monomer, insoluble Aβ42, soluble Aβ42, insoluble Aβ40, soluble Aβ40, conjugated dienes and F 2 -isoprostanes) were analyzed in the linear regression model. The results indicated that conjugated dienes were a strong predictor of apoD dimer levels (t = 3.481, p = 0.002). Both insoluble and soluble Aβ42 were also significant in this model (t = 2.422, p = 0.024 and t = -2.785, p = 0.011, respectively). We measured variance inflation factor values (VIF), that quantify the severity of multicolinearity for these variables, and found them to be 5.861 and 7.034, respectively. VIF values greater > 5.0 are considered as an indicator of high multicolinearity [45] . We therefore removed the soluble Aβ42 and soluble Aβ40 variables from the regression analysis to resolve the potential confounding affects of multicolinearity [45] . The revised model revealed that conjugated dienes were the only significant predictor of apoD dimer levels (t = 2.151, p = 0.041). All VIF values were < 2.6 in this analysis.
Furthermore, when conjugated diene concentration was assigned as the dependent variable in this model, only apoD dimer levels were significantly correlated (t = 2.237, p = 0.034).
Overall this analysis suggests that conjugated diene levels are the strongest predictor of apoD dimer levels in the AD hippocampus. In addition, the association between apoD dimer levels
and Aβ deposition appears to be secondary to the conjugated diene marker of lipid peroxidation. The F 2 -isoprostane marker of lipid peroxidation does not appear to correlate with either Aβ accumulation or apoD dimerization in this cohort of post-mortem samples.
Discussion
The data presented in this study show that soluble apoD levels increase as the severity of AD pathology increases. This change in apoD expression occurs in the hippocampus but not in the cerebellum; the latter representing an area of the brain that is relatively spared in AD.
Interestingly, the level of the dimerized form of apoD, that we have previously shown is promoted as a consequence of the interaction between apoD Met 93 with L-OOHs [23, 39] , is predominantly increased in the latest stages of AD pathology. Moreover, this late increase in apoD dimerization appears to be more closely related to lipid conjugated diene levels (a lipid peroxidation marker) than it is to insoluble Aβ levels. While such associations cannot be used to define a precise mechanism for the increased apoD dimerization in AD, one plausible explanation is that during the course of AD progression lipid peroxidation begins to increase.
This may be related to the radical formation induced by Aβ42 [12, 52] as well as several other pathways [53, 54] . We speculate that along with other small molecule (e.g. ascorbate, glutathione) and enzymatic (e.g. superoxide dismutase, glutathione peroxidase) antioxidant defenses, apoD upregulation represents a homeostatic response that helps to combat lipid peroxidation.
The hydrophobic patch located close to the entrance of the apoD ligand binding pocket contains an exposed Met 93 side chain that can directly reduce radical-propagating L-OOHs [23, 39] . So long as this crucial Met residue can be maintained in a native state via the action of methionine sulfoxide reductase (MSR), the lipid antioxidant function of apoD can be theoretically maintained. However, if the levels of lipid peroxidation in the hippocampus surpass the antioxidant capacity of apoD and other antioxidant defenses, we predict that the steady state concentration of apoD containing Met 93 sulfoxide (Met 93 SO) will be increased such that its propensity to self-associate is increased and the presence of apoD dimers in the insoluble fraction of hippocamapal homogenates will also increase. In this respect, apoD dimerization may be considered as a de facto marker of the extent of hippocampal lipid peroxidation.
The factors that may trigger the increase in lipid peroxidation (assessed as lipid conjugated dienes) and apoD dimerization in late stages of AD are not clear. This could be related to higher levels of both soluble and insoluble Aβ42 we have detected in the Group V/VI samples (which could promote radical production [52] ), or it may be related to an impaired capacity for redox cycling of apoD Met 93 SO back to Met 93 . In line with this latter suggestion, MSR levels are decreased by ~50% in the AD hippocampus but unchanged in the cerebellum [55] .
Another intriguing finding in our current study relates to the apparent discrepancy when the lipid conjugated diene levels and F 2 -isoprostane levels were compared. Unexpectedly, these markers of lipid peroxidation were not significantly correlated either in the hippocampus (Table 2) or across the whole data set including the cerebellum and hippocampus (data not shown). The reasons for this lack of correlation are not clear. It should be noted that F 2 -isoprostanes are derived from arachidonic acid whereas lipid conjugated dienes are derived from all unsaturated acyl chains that have been subjected to radical attack; i.e. the methods are measuring different products as indices of lipid peroxidation. It is clear, however, that F 2 -isprostane levels are increased in the Braak stage III/IV cases in the hippocampus while there were no changes in the cerebellum of the same cases (Fig 5A and Fig 5B, respectively) . This is in general agreement with previous findings that suggest cerebrospinal fluid F 2 -isoprostane levels may reflect cerebral lipid peroxidation and thus be a useful biomarker for subjects who may proceed to AD [54, 56] .
In summary, our studies reveal that soluble apoD levels are associated with AD Braak stage, whereas apoD dimer formation appears to increase predominantly in the advanced stages of 
